NIH TRND program: Successes in preclinical therapeutic development

Trends in Pharmacological Sciences

Volumn 34, Issue 2, 2013, Pages 87-89

  McKew, John C ^a   Pilon, Andre M ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; AES 103; AMINOSUGAR; ANTINEOPLASTIC AGENT; DEX M 74; HEMATOLOGIC AGENT; HYDROXYUREA; N ACETYL DEXTRO MANNOSAMINE; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; HEREDITARY INCLUSION BODY MYOPATHY; HUMAN; LAW; MARKETING; MEDICAL RESEARCH; MYOPATHY; NATIONAL HEALTH ORGANIZATION; NEGLECTED DISEASE; NIEMANN PICK DISEASE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; RARE DISEASE; SICKLE CELL ANEMIA; TRANSLATIONAL RESEARCH; UNSPECIFIED SIDE EFFECT;

EID: 84873409002     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2012.10.001     Document Type: Note

References (9)

1. B. Munos Lessons from 60 years of pharmaceutical innovation Nat. Rev. Drug Discov. 8 2009 959 968
2. S.M. Paul How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat. Rev. Drug Discov. 9 2010 203 214
3. US Congress (1983) Orphan Drug Act, Public Law 97-414
4. US Congress (1984) Health Promotion and Disease Prevention Amendments of 1984, Public Law 98-551
5. F.S. Collins Reengineering translational science: the time is right Sci. Transl. Med. 3 2011 90cm17
6. D.J. Adams The Valley of Death in anticancer drug development: a reassessment Trends Pharmacol. Sci. 33 2012 173 180
7. L. Pauling Sickle cell anemia, a molecular disease Science 109 1949 443
8. W.K. Hoots, and S.B. Shurin Future directions of sickle cell disease research: the NIH perspective Pediatr. Blood Cancer 59 2012 353 357
9. S.J. Weir Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnership Cancer Res. 72 2012 1055 1058